Nanology Labs, an IND-stage company developing next generation nanomedicines to conquer cancer, announced, on May 17, that its seed capital raise was oversubscribed at $3M. The round was led by FACIT with co-investors Creative Destruction Lab Angels, Ontario Brain Institute, Ontario Center of Innovation, and MEDTEQ.
KA Imaging Installs Two New Mobile X-Ray Units at University Health Network
KA Imaging, a developer of innovative X-ray imaging technologies and systems, today announced that it has installed two new mobile X-ray units within the University Health Network (UHN) to enhance current clinical studies and support patient care. One new unit is being used at the Princess Margaret Cancer Centre, and the other at the Toronto General Hospital.
HeadworX Chooses OBIO's 2019 Summit Company, VoxNeuro Innovation To Enhance Patient Care
A leading neurophysiological testing facility has selected VoxNeuro’s innovative technology to provide its patients with more certainty in the diagnosis and treatment of brain conditions, VoxNeuro announced.
HeadworX, led by neurologist Dr. Abdel Kaleel, MD, M.Sc in Kitchener-Waterloo, is integrating VoxNeuro’s groundbreaking Cognitive Health Assessment™ into its clinical practice.
Governor General's Innovation Award Winners Include Leaders of Swift Medical, Adaptiiv
The Rideau Hall Foundation has announced the 2021 winners of the Governor General’s Innovation Awards. This year, six individuals and groups have secured the honour, including two key members of Canadian healthtech startups.
This year’s list of recipients includes Sheila Wang, co-founder and chief medical officer of Toronto-based healthtech startup Swift Medical, for her creation of Swift’s artificial intelligence (AI)-powered remote wound care monitoring solution. The company’s mobile app captures and shares high-precision wound images from home.
CTI Life Sciences Fund Raises $100 Million in First Close of Third Venture Fund
Montréal-based venture capital firm CTI Life Sciences Fund has raised $100 million CAD in the first close of its third venture fund. The fund’s limited partners include previous investors such as Fonds de solidarité FTQ, Caisse de dépôt et placement du Québec, Investissement Québec and Teralys Capital. Other investors include BDC Capital’s fund investments team.
Triumvira Appoints Teresa McRoberts as Chief Financial Officer and Announces Senior Level Promotions
AUSTIN, Texas & HAMILTON, Ontario - Triumvira Immunologics, a privately held biopharmaceutical company developing a novel platform for engineering T cells to attack cancers, today announced the appointment of Teresa McRoberts as Chief Financial Officer. The Company also announced the promotion of Andreas Bader, Ph.D. to Chief Scientific Officer and Jon Irvin to Senior Vice President of Finance.
Register by May 25 to Learn About Creating Your Best Pitch with Brian Bordley, Investor, SkyDeck Fund
Ontario Life Science, Medtech and Health Information Technology companies looking to improve their pitches are invited to join this conversation.
With experience investing in over 100 startups, and hearing countless pitches, Brian Bordley, will share his views about the elements required to deliver an effective “pitch” and what should be avoided. From VC identification to pitch follow-up, Brian will address winning strategies, common mistakes, and how best to secure an elusive Silicon Valley introduction.
This one-hour session will feature Brian Bordley, Venture Capitalist and Principal, SkyDeck Fund, Berkeley Ventures, University of California, Berkeley, California.
A Registration form will be available in the next few days. In the meantime, please think about any burning questions you would like to have answered, and send them in advance to Marisa at: Marisa.goepel@international.gc.ca. Brian will do his best to address all of your concerns.
When: June 1 from 12:00 pm to 1:00 pm
Please visit https://skydeck.berkeley.edu/ to learn more about SkyDeck.
Treadwell Announces Initiation of Patient Dosing in TWT-202, a Phase 1b/2 study of PLK4 Inhibitor, CFI-400945, in Patients with Leukemia
NEW YORK - Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, announced on April 29, the initiation of patient dosing in TWT-202, its Phase 1b/2 study to evaluate its CFI-400945, an oral, first-in-class inhibitor of Polo-like kinase 4 (PLK4) in patients with Leukemia as a monotherapy or in combination with hypomethylating agents. Dosing of the first patient in the trial commenced April 16th at the University of Texas MD Anderson Cancer Center, Houston, TX.
VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)
VBI Vaccines Inc., a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, announced yesterday that preclinical data of VBI’s enveloped virus-like particle (eVLP) vaccine candidate, VBI-2902, has been submitted for peer-review to a scientific journal and will be available on the online preprint server, bioRxiv.
Register by May 3! Learn About Taiwan Biotech Sector Opportunities
Taiwan Bio Industry Organization and Canadian Trade Office in Taipei and the Ontario Ministry of Economic Development, Job Creation and Trade (MEDJCT) will be holding a webinar to introduce the biotech sector opportunities in Taiwan as well as the upcoming BioAsia Taiwan in July 2021.
BIO Asia–Taiwan is Asia's largest biotech partnering and networking event, attracting and engaging thousands of global biotech leaders, innovators, and investors each year. For 2021, the BIO Asia–Taiwan Conference and Exhibition will continue its transition to a hybrid event format – Online + Onsite. This gathering of international industry notables in both online and onsite spaces will provide delegates access to new industry developments and insights, and with critical connections made via BIO One-on-One Partnering™ participants will be well positioned for success in the post-pandemic era.
Organizer: Taiwan Bio Industry Organization
Partners: Canadian Trade Office in Taipei
Ontario Ministry of Economic Development, Job Creation & Trade
Date and Time:
20:00-21:00 (EDT) Toronto, May 5 (Wed)
21:00-22:00 (ADT) Halifax, May 5 (Wed)
19:00-20:00 (CDT) Winnipeg, May 5 (Wed)
18:00-19:00 (MDT) Calgary, May 5 (Wed)
17:00-20:00 (PDT) Vancouver, May 5 (Wed)
08:00-09:00 am (Taipei time) May 6 (Thu)
Versant Ventures Raises $950 Million Across Three Vehicles
Versant Ventures, on April 21, announced $950 million in additional capital allocated across a platform of three separate vehicles. These included Versant Venture Capital VIII, a $560 million primary global biotech fund; Versant Voyageurs II, a $140 million booster fund; and Versant Vantage II, a $250 million later-stage opportunity fund.
Learn More about the Translational Research Program
If you want to learn how to have a tangible impact on patient care and be part of spearheading interventions that improve health, then the Translational Research Program, at University of Toronto, may be a program tailor-made for you.
Canada’s Biotech Industry Will Need to be Stronger if We Want to be Ready for the Next Pandemic
OBIO's Investment Summit keynote speaker and 2020 Nobel Prize Laureate, Michael Houghton, wrote an opinion piece which speaks to how Canada can better prepare for the next pandemic. "We are at a critical point in the fight against COVID-19. Vaccine rollouts across the country are ramping up, but COVID-19 still has the upper hand with several provinces once again reinstating restrictions. The pandemic has taught us many hard lessons – and one of the most critical is that Canada needs to develop and produce vaccines at home."
MCI Onehealth Announces Investment in and Commercial Support for Acorn Biolabs, Inc.
MCI Onehealth Technologies Inc., a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, has announced an investment of $250,000 with Acorn Biolabs, Inc. (“Acorn Biolabs,” “Acorn”), a Toronto-based biotechnology company. Acorn Biolabs is revolutionizing regenerative and precision medicine
Canada-Israel Cardiovascular Innovation Forum Announced Selected Applications
The Organizing Committee of the Canada Israel Cardiovascular Innovations Forum is pleased to announce the innovation applications selected for presentation on April 25, 2021. The program will start at 12:00 PM (noon) Toronto, 19:00 Israel.
Israeli Technology:
Lihu Avitov, Revamp Medical; “The Doraya Catheter - a novel temporary intravenous flow regulator”
Nitai Hanani, Paragate Medical, “Implantable Peritoneal Ultrafiltration Device (IPUD), for continuous & active fluid decongestion in heart failure patients”
Elon Reshef, Invatin Technologies; “A Novel Continuous Stroke Prevention Device”
Ariel Weigler, Cuspa Ltd, “Transcatheter artificial cusp for repair of valve insufficiency”
Canadian Technology:
Stephanie Buryk-Iggers, SPARKED; “Handheld, non-invasive device for early risk detection of cardiovascular disease”
Daniel Gelman, Aufero Medical, “Device to stabilize contact force during radiofrequency catheter ablation therapy for atrial fibrillation”
Surath Gomis, Arma Biosciences, “A handheld device for rapid, continuous remote monitoring of biochemical markers in patients with heart failure”
Ali Tavallaei, Magellan Biomedical, “A novel catheter allowing for accurate localized steering and tracking of endoluminal devices”
Ryan Tennant, “A novel re-entry device for angioplasty of coronary and peripheral chronic total occlusions”
We invite you to attend the First Canada-Israel Cardiovascular Innovation Forum on April 25.
Ripple Therapeutics Announces First Patient Treated in Phase II Trial Evaluating IBE-814 IVT in DME and RVO
Ripple Therapeutics Corporation, a clinical stage, ophthalmology-focused developer of novel pharmaceuticals, announced, on April 20, that the first patient has been treated in RIPPLE-1, a Phase II trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases.
Registration is Open! Canada Korea Business Forum 2021
Participants will hear from the experts on Canada-Korea venture investment, merger, joint venture, financing and direct investment deals.
When: Wednesday, May 12 at 7:00 - 9:30 pm ET
Dialogue Closes TSX IPO, Raising $100 Million
Telehealth startup Dialogue Health Technologies has gone public on the Toronto Stock Exchange (TSX), raising $100 million through its previously announced initial public offering (IPO). The Montréal-based firm began trading on March 30, on the TSX under the symbol “CARE.”
PlantForm signs agreement with Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab cancer dru
PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market.
"This agreement advances PlantForm's global strategy for biosimilar drug development and manufacturing to increase affordability and access to a wide range of life-saving medications." said Dr. Don Stewart, PlantForm's President and CEO.
Aspect Biosystems and JSR Corporation Enter Collaboration to Develop Bioprinted Vascularized Tissues for Regenerative Medicine
Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation.